Bagai Shaun 4

What Happened
Shaun Bagai, CEO of RenovoRx, was granted 946,107 stock options on April 3, 2026 (transaction reported on Form 4 filed April 7, 2026). The grant is reported at $0.00 (no cash paid at grant). These are derivative awards (options), not an immediate stock purchase or sale.

Key Details

• Transaction type/code: Award/Grant (A), derivative options reported at $0.00.
• Grant size: 946,107 options total — 111,621 incentive stock options (ISOs) and 834,486 non-qualified stock options (NQSOs).
• Vesting: Over four years at 1/48 per month with no cliff, vesting commencement effective January 1, 2026; fully vested January 1, 2030.
• Exercisability: Options will only become exercisable when there is an effective registration statement covering the underlying shares.
• Expiration: Options expire April 3, 2036.
• Filing/timeliness: Transaction date April 3, 2026; Form 4 filed April 7, 2026 — appears to be within the standard two-business-day reporting window.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote: See F1 for details on ISO vs. NQSO split, vesting schedule, exercisability condition, and expiration.

Context
This was a grant of stock options (a common form of executive compensation) rather than an outright purchase or sale of shares. Because the options are not exercisable until an effective registration statement is in place, there is no immediate increase in publicly tradable shares from this grant. Grants report a $0.00 price on Form 4, which reflects the award nature of the transaction rather than a cash purchase.